Norlase secures $11 million in funding
Key takeaways:
- Norlase secured $11 million in funding, led by West Hill Capital.
- The funding will be used to meet production demands for the Echo pattern laser.
Norlase secured $11 million in funding following the FDA clearance and CE mark approval of the Echo green pattern laser photocoagulator, according to a press release.
West Hill Capital led the funding, which will be used to help the company meet the production demands for the Echo and other laser treatments.
“This incredible technology reduces what is today a large 100-pound piece of equipment into a device you can hold in the palm of your hand and easily attach to existing slit lamps,” Oliver Hvidt, CEO and co-founder of Norlase, said in the release. “The launch of Echo in the USA and EU, combined with the growing demand for our Lion laser indirect ophthalmoscope and Leaf single-spot laser, means we need to drastically expand our production and global market presence.”
Norlase will also use the funding to continue development of ophthalmic innovations in the company’s pipeline.
Read more about